Home » Graduate Program (2018-2022) » Publications » Project 5

Amyloid beta and its degrading enzyme neprilysin as targets for treatment of liver fibrosis and prevention of hepatocellular carcinoma

10 project-relevant publications [ICEPHA PI(s) and PhD student(s) in bold letters] 

  1. Abdel-Kahaar E, Winter S, Tremmel R, Schaeffeler E, Olbricht CJ, Wieland E, Schwab M, Shipkova M, Jaeger SU. 2019. The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant Center. Front Genet 10:871. doi:10.3389/fgene.2019.00871
  2. Buniatian GH, Weiskirchen R, Weiss TS, Schwinghammer U, Fritz M, Seferyan T, Proksch B, Glaser M, Lourhmati A, Buadze M, Borkham-Kamphorst E, Gaunitz F, Gleiter CH, Lang T, Schaeffeler E, Tremmel R, Cynis H, Frey WH, 2nd, Gebhardt R, Friedman SL, Mikulits W, Schwab M, Danielyan L. 2020. Antifibrotic Effects of Amyloid-Beta and Its Loss in Cirrhotic Liver. Cells 9:doi:10.3390/cells9020452
  3. Pan L, Shan S, Tremmel R, Li W, Liao Z, Shi H, Chen Q, Zhang X, Li X. 2023. HTCA: a database with an in-depth characterization of the single-cell human transcriptome. Nucleic Acids Res 51:D1019-D28. doi:10.1093/nar/gkac791
  4. Schafer R, Schwab M, Siegel G, von Ameln-Mayerhofer A, Buadze M, Lourhmati A, Wendel HP, Kluba T, Krueger MA, Calaminus C, Scheer E, Dominici M, Grisendi G, Doeppner TR, Schlechter J, Finzel AK, Gross D, Klaffschenkel R, Gehring FK, Spohn G, Kretschmer A, Bieback K, Kramer-Albers EM, Barth K, Eckert A, Elser S, Schmehl J, Claussen CD, Seifried E, Hermann DM, Northoff H, Danielyan L. 2020. Modulating endothelial adhesion and migration impacts stem cell therapies efficacy. EBioMedicine 60:102987. doi:10.1016/j.ebiom.2020.102987
  5. Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, Bohringer S, Cambon-Thomsen A, Cecchin E, Cheung KC, Deneer VH, Dupui M, Ingelman-Sundberg M, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Mitropoulou C, Rial-Sebbag E, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Davila Fajardo CL, Dolzan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Guchelaar HJ, Ubiquitous Pharmacogenomics C. 2023. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet 401:347-56. doi:10.1016/S0140-6736(22)01841-4
  6. Tremmel R, Klein K, Battke F, Fehr S, Winter S, Scheurenbrand T, Schaeffeler E, Biskup S, Schwab M, Zanger UM. 2020. Copy number variation profiling in pharmacogenes using panel-based exome resequencing and correlation to human liver expression. Hum Genet 139:137-49. doi:10.1007/s00439-019-02093-7
  7. Tremmel R, Nies AT, van Eijck BAC, Handin N, Haag M, Winter S, Buttner FA, Kolz C, Klein F, Mazzola P, Hofmann U, Klein K, Hoffmann P, Nothen MM, Gaugaz FZ, Artursson P, Schwab M, Schaeffeler E. 2022. Hepatic Expression of the Na(+)-Taurocholate Cotransporting Polypeptide Is Independent from Genetic Variation. Int J Mol Sci 23:doi:10.3390/ijms23137468
  8. van Tilburg CM, Pfaff E, Pajtler KW, Langenberg KPS, Fiesel P, Jones BC, Balasubramanian GP, Stark S, Johann PD, Blattner-Johnson M, Schramm K, Dikow N, Hirsch S, Sutter C, Grund K, von Stackelberg A, Kulozik AE, Lissat A, Borkhardt A, Meisel R, Reinhardt D, Klusmann JH, Fleischhack G, Tippelt S, von Schweinitz D, Schmid I, Kramm CM, von Bueren AO, Calaminus G, Vorwerk P, Graf N, Westermann F, Fischer M, Eggert A, Burkhardt B, Wossmann W, Nathrath M, Hecker-Nolting S, Fruhwald MC, Schneider DT, Brecht IB, Ketteler P, Fulda S, Koscielniak E, Meister MT, Scheer M, Hettmer S, Schwab M, Tremmel R, Ora I, Hutter C, Gerber NU, Lohi O, Kazanowska B, Kattamis A, Filippidou M, Goemans B, Zwaan CM, Milde T, Jager N, Wolf S, Reuss D, Sahm F, von Deimling A, Dirksen U, Freitag A, Witt R, Lichter P, Kopp-Schneider A, Jones DTW, Molenaar JJ, Capper D, Pfister SM, Witt O. 2021. The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discov 11:2764-79. doi:10.1158/2159-8290.CD-21-0094
  9. Wiest R, Weiss TS, Danielyan L, Buechler C. 2021. Serum Amyloid Beta42 Is Not Eliminated by the Cirrhotic Liver: A Pilot Study. J Clin Med 10:doi:10.3390/jcm10122669
  10. Schwinghammer UA, Melkonyan MM, Hunanyan L, Tremmel R, Weiskirchen R, Borkham-Kamphorst E, Schaeffeler E, Seferyan T, Mikulits W, Yenkoyan K, Schwab M, Danielyan L. 2020. α2-Adrenergic Receptor in Liver Fibrosis: Implications for the Adrenoblocker Mesedin. Cells 18;9(2):456. doi: 10.3390/cells9020456